BAE's H1-26 beat is a capex story wearing a growth multiple

BAE Systems delivered a strong first half of 2026, with a rising order backlog and guidance for 8 to 12 percent operating profit growth ^[1][2]. In the same accounts, according to a Seeking Alpha analysis that keeps a Hold on the shares, free cash flow is down 17 percent and operating cash flow down 9 percent since 2023, while capital expenditure and intangibles rise ^[3][4][8].

That divergence is the story. Earnings per share is climbing while the cash meant to underwrite it moves the other way ^[3]. The author's term for this is weakening cash conversion, and the conclusion is a question mark over earnings quality rather than over demand ^[5].

The shape of the gap is more informative than the label. Free cash flow is falling roughly 1.9 times as fast as operating cash flow ^[1], which places most of the deterioration below the operating line: it is in what BAE is spending on plant and intangible assets, not only in what it collects from customers ^[4]. That is what an order book of this kind costs. Capacity has to be built before it can be billed, and the bill arrives several years before the margin does. It is a defensible way to run a defence contractor. It is not a growth-company cash profile.

Which is the problem with the price. The same analysis calls the current 26 to 29 times earnings excessive and well above BAE's historical norms, while still describing the business as high quality ^[6]. At that range the earnings yield is roughly 3.4 to 3.8 percent ^[2], and investors are being asked to pay a re-rated multiple during the investment phase of the cycle rather than the harvest. The analyst raised the price target to GBP 16 per share, equivalent to 86 dollars for the ADR, but held the rating, citing valuation and cash flow risk and waiting for the multiple to normalise ^[7][8].

Provenance matters here, because this is one voice, not a consensus. The author states plainly that they are not a CFA and are not licensed to give financial advice ^[9], and has been conservative to negative on defence names since the surges that followed Russia's invasion of Ukraine, while accepting the broader European rearmament thesis ^[10]. The disclosure attached to the piece lists a long position in RYCEF, and says the author holds the European listings rather than the ADRs of European companies discussed ^[11]. The published summary also gives percentage changes and a P/E range without absolute figures for cash flow, capex or backlog ^[12], so the direction of travel is verifiable from it and the magnitude is not.

What to watch is whether the second half shows capex peaking. If spending plateaus while revenue from the backlog starts to land, free cash flow recovers and the multiple has something to grow into ^[1][4]. If capex and capitalised intangibles keep climbing into another year of double-digit profit guidance ^[2], the market is funding a manufacturing build-out at 26 to 29 times earnings ^[6], and the re-rating, not the rearmament, is what will correct first.